Glial Modulators for Huntington's Disease White Matter Abnormalities

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Huntington's disease do not effectively address the cellular and molecular underpinnings of glial pathology, particularly in relation to white matter abnormalities and dysmyelination.

Innovation Solution

Administering modulators of specific glial cell differentiation regulation genes, myelination-associated genes, oligodendrocyte differentiation genes, gliogenesis regulation genes, neuron ensheathment genes, axon guidance genes, neuron projection guidance genes, axonogenesis genes, and axon development genes to subjects at risk or with Huntington's disease, under conditions effective to treat or inhibit the onset of the disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for Huntington's disease are used, then symptomatic management is provided, but the cellular and molecular underpinnings of glial pathology and white matter abnormalities are not effectively addressed

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidcomplexity of treatment mechanism

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses modulators of glial cell differentiation regulation genes as intermediary substances to bridge the gap between current symptomatic treatments and the underlying glial pathology. These modulators specifically target glial cells and their differentiation processes, acting as mediators that address the root cause of white matter abnormalities while being administered through conventional therapeutic routes

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies parameter changes by modulating the expression levels of specific genes (BMP2, LINGO1, MAG, NKX2-2, NR2E1, NTRK3, OLIG2, SERPINE2, SIRT2, TCF7L2) that regulate glial cell differentiation. By changing the expression parameters of these key genes, the treatment effectively addresses glial pathology and white matter abnormalities without requiring complex procedural interventions

Inventive Principle:

Principle #35Parameter changes

2Reliability

If modulators of glial cell differentiation genes are administered, then glial pathology and white matter abnormalities are addressed, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improveaddressing of glial pathologyVSAvoidcomplexity of treatment protocol

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs modulators that can target multiple genes involved in glial cell differentiation (BMP2, LINGO1, MAG, NKX2-2, NR2E1, NTRK3, OLIG2, SERPINE2, SIRT2, TCF7L2) with a single therapeutic approach. This multi-functional modulator strategy addresses various aspects of glial pathology simultaneously, reducing the need for multiple separate treatments and simplifying the overall protocol while maintaining comprehensive efficacy

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12303549B2Methods of treating or inhibiting onset of Huntington's disease

Publication Date: 2025.05.20 UNIVERSITY OF ROCHESTER

AI summary

The disclosure herein relates generally to a method of treating or inhibiting onset of Huntington's disease. This method involves selecting a subject having or at risk of having Huntington's disease and administering to the subject one or modulators of one or more genes as described herein, or proteins encoded therefrom, under conditions effective to treat or inhibit onset of Huntington's disease in the subject.